Droxidopa Capsule
Product Images NDC 69452-256

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Droxidopa (NDC 69452-256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemicalstructure (Chemicalstructure)

Chemical structure of droxidopa showing the molecular arrangement including hydroxyl groups, an amino group, and a carboxylic acid group, consistent with the active ingredient droxidopa.*

FDA Label Image

Containerlabel100mg (Containerlabel100mg)

Label for Droxidopa Capsules, 100 mg strength, oral dosage form. The label indicates a package size of 90 capsules and is marked Rx Only. It includes storage instructions, manufacturer information for Bionpharma Inc. in Princeton, NJ, and a barcode. The label states each capsule contains 100 mg of droxidopa and provides usual dosage and warning information.*

FDA Label Image

Containerlabel200mg (Containerlabel200mg)

Droxidopa Capsules 200 mg oral dosage form label showing a 90-capsule package. The label indicates the product is prescription only (Rx Only) and includes storage instructions and manufacturer information for Bionpharma Inc.*

FDA Label Image

Containerlabel300mg (Containerlabel300mg)

Label for Droxidopa Capsules 300 mg by Bionpharma Inc. The label specifies the product is prescription-only and contains 90 capsules. Storage instructions, dispensing instructions, a warning about colors and additives, manufacturer address, barcode, and revision date (04/2019) are visible.*

FDA Label Image

Figure1 (Figure01)

Line graph showing mean change in dizziness over 8 weeks of a double-blind treatment phase comparing Droxidopa and placebo. The graph includes error bars, with a significant difference indicated (p<0.05) at week 1, and shows greater improvement in dizziness for Droxidopa compared to placebo.*

FDA Label Image

Figure2 (Figure02)

A bar chart comparing the percentage of subjects reporting improvement in OHSA Question 1 between placebo and droxidopa groups. The x-axis represents improvement scores ranging from -8 (worse) to 8 (better), and the y-axis shows the percent of subjects. White bars indicate placebo, and black bars indicate droxidopa.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.